Figure 8.

MMP-9/TIMP-1 levels are increased in PFC samples from MDD patients treated with monoamine antidepressants. A, B, Compared with control patients, monoamine antidepressant-treated patients (ADD) have increased levels of MMP-9 in the PFC (A, p = 0.0130, one-way ANOVA with Dunnett's multiple comparisons). In contrast, there is no significant difference between MMP-9 levels in control and untreated MDD patients (p = 0.45). Moreover, there is a significant increase in the MMP-9/TIMP-1 ratio in monoamine antidepressant-treated MDD patients compared with the same ratio in controls or untreated MDD patients (Control vs MDD + ADD, p = 0.0052, one-way ANOVA with Tukey's multiple comparisons; MDD vs MDD + ADD, p = 0.009, one-way ANOVA with Tukey's multiple comparisons). *p < 0.05.